This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Cardinal (CAH) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Any Bright Spot in Q1 Earnings? Sector ETFs & Stocks to Buy
by Sweta Killa
First-quarter results are likely to be bleak, given that the coronavirus outbreak are weighing on corporate profits. However, there are still some bright spots. Let's have a look.
Will Brand Building Efforts Aid Aphria (APHA) in Q3 Earnings?
by Zacks Equity Research
Aphria's (APHA) focus on enhancing its brands and profitability is likely to have boosted its top line in third-quarter fiscal 2020.
5 Broker-Friendly Stocks Amid Coronavirus-Led Pandemonium
by Maharathi Basu
Brokers have lot more information on a company's profile and its prospects than individual investors as the former attends conference calls, company presentations and interact with management as well.
Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?
by Zacks Equity Research
Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Koninklijke Philips, Dropbox, Cardinal Health, Enphase Energy and Chemed
5 Great Dividend Growth Stocks for Your Portfolio
by Sweta Killa
The stocks that have a strong history of dividend growth as opposed to those that offer high yields form a healthy portfolio with more scope for capital appreciation.
Can Product Innovation Aid OrganiGram (OGI) in Q2 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and ongoing product innovation in the fiscal second quarter.
Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.
Cardinal Health's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Cardinal Health
U.S. Economy Likely to Reopen in May: 5 Top Growth Picks
by Nalak Das
Although the death toll continues to go up in the United States, the curves related to hospitalization, intensive-care check-ins and intubations are gradually flattening.
Top Ranked Income Stocks to Buy for April 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 13th.
Top Ranked Income Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 8th.
Zacks.com featured highlights include: Ampco-Pittsburgh, Kaleyra, Booz Allen Hamilton, Grocery Outlet and The Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: Ampco-Pittsburgh, Kaleyra, Booz Allen Hamilton, Grocery Outlet and The Cardinal Health
How Cardinal Health (CAH) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Cardinal Health (CAH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 07, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: InMode, Integer, Cardinal Health, DaVita and The Ensign Group
Focus on Relative Price Strength to Soften the Coronavirus Blows
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns in the time of coronavirus? Tap these stocks with explosive relative price strength.
5 Stocks to Buy for 5 Good Reasons
by Sejuti Banerjea
Here are 5 ways to make the most of a difficult market.
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DVA, CAH, TGNA, SLM and AMX
Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better
by Zacks Equity Research
Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.
Can Economic Stimulus Save MedTech From Coronavirus Doldrums?
by Trina Mukherjee
Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.
5 Top Value Stocks to Buy in a Volatile April
by Nalak Das
Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.
3 Must-Buy Stocks as Coronavirus Cases Spike (Revised)
by Zacks Equity Research
COVID-19 has increased the demand for ventilators and personal protective equipment, which can aid these three companies at large.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - April 01, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?